| My Account | Sitemap | Subscribe | Contact Us | Help |
Home
Diabetes Health
Diabetes Health Professional
- Foot Care for Diabetics
Richard K. Bernstein, MD, discusses 19 proven ways to take care of your feet and avoid diabetes-related complications
- Broncos QB Steps into the Pocket with Type 1
Scott Brown writes about Denver Broncos quarterback Jay Cutler's life since his recent type 1 diagnosis
- Diabetes and Eating Disorder Come Together as Diabulimia
Justine Lorelle Blanchard looks at a chilling development among type 1 teens: skipping insulin shots and purging food as a way to achieve rapid weight loss
- Teens on Insulin Pumps: Are They Safe?
Beth Morrow follows up on an article we published in May about teens' problems — occasionally fatal — with insulin pumps
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
Diabetes Health Digital Advantage™, the free, online version of Diabetes Health magazine, virtually identical to the bi-monthly Diabetes Health print magazine, has many additional useful features.
While the pages turn in a similar fashion to a magazine's, direct hot links lead to research articles, products and advertiser sites.
Access to the amazing Diabetes Health Digital Advantage™ is through any web browser, so you can read the current issue of Diabetes Health magazine online wherever you are!
The must-have resource for physicians, educators and medical professionals who focus on the treatment of diabetes.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Latest Byetta Articles
Byetta (exenatide), which has been on the market since 2005, has become a popular twice-daily treatment for glucose control. Its beneficial side effects include significant weight loss and lowered A1c’s, as well as appetite control.
Byetta Breaks the Piggy Bank
Amylin Reports Quarterly Loss Due to Costs of Developing a Once-Weekly Form of Byetta
San Diego-based Amylin Pharmaceuticals, Inc., posted a second-quarter loss of $64.8 million, or 47 cents per share. This compares to a 2007 second-quarter loss of 45 million, or 34 cents a share.
The per-share loss was two cents below what Wall Street analysts had predicted.
Analysts say the reason for the loss is the increased research and development expense posed by Amylin’s development of a once-weekly form of its type 2 diabetes treatment drug, Byetta.
Byetta (exenatide), which has been on the market since 2005, has become a popular twice-daily treatment for glucose control. Its beneficial side effects include significant weight loss and lowered A1c’s, as well as appetite control.
Amylin is now spending significant sums on the creation of a once-weekly form of the drug, which is now in Phase 3 trials. The company plans to apply for final FDA approval of the drug by this time next year.
Second-quarter sales of Byetta reached $177.5 million—about 79 percent of the company’s total of $224.3 million in revenues. Research costs in the same period amounted to $75.4 million, while overall sales, management, and administrative costs reached $111 million.
Share on Facebook
Share on MySpace 
Share on Digg
You May Also Be Interested In...
147 comments - 29 Nov 2007
94 comments - 22 Aug 2007
81 comments - 14 Aug 2008
52 comments - 18 Jan 2008
Comments
It's shameful that Wall Street has so much influence over the development of life-saving drugs. I worked for a San Diego biotech and saw first hand how Wall Street interferrs with the important work of research.
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register..
Register your Diabetes Health Username here.
Have Your Say...